Výsledky vyhledávání - "Immunological/adverse effects"

Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis:case report

Autor: Rikke Boedker Holmstroem, Emilie Kristine Dahl, Morten Helms, Henrik Vedel Nielsen, Janne Bayer Andersen, Jacob Tveiten Bjerrum, Inge Marie Svane, Eva Ellebaek, Jakob Benedict Seidelin

Publikováno v: Holmstroem, R B, Dahl, E K, Helms, M, Nielsen, H V, Andersen, J B, Bjerrum, J T, Svane, I M, Ellebaek, E & Seidelin, J B 2022, ' Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis : case report ', BMJ Open Gastroenterology, vol. 9, no. 1, e000989 . https://doi.org/10.1136/bmjgast-2022-000989

BackgroundImmune checkpoint inhibitors (ICIs) can induce a wide range of immune-related adverse events (irAEs), potentially affecting any organ. ICI-induced colitis is a frequently reported irAE, whereas enteritis is rare and not well documented.Case

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4c058cd1452d0daf71f568c62b551a9
https://curis.ku.dk/portal/da/publications/tofacitinib-and-faecal-microbiota-transplantation-in-treating-checkpoint-inhibitorinduced-enterocolitis(9a254421-b5ef-4cb4-83ad-938ac9ad0619).html

Zobrazit plný text záznamu

Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports

Autor: Marco Zezza, Nelly Pitteloud, Haithem Chtioui, Laura Marino, Faiza Lamine, Carine Mekoguem, Christophe Kosinski

Publikováno v: BMC Endocrine Disorders, Vol 19, Iss 1, Pp 1-5 (2019)
BMC Endocrine Disorders
BMC endocrine disorders, vol. 19, no. 1, pp. 144

BackgroundThe use of immune checkpoint inhibitor (ICI) therapy is becoming a standard of care for several cancers. Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1) or its ligand (PD-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a722f98fa2436ff73199210f96e9153
https://doaj.org/article/5e85b5b762c841489b8519ccf9b5cc94

Zobrazit plný text záznamu

Plný text ve formátu HTML

MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors

Publikováno v: JCI Insight, Vol. 5, No 6 (2020) P. 1317
JCI Insight

Immune checkpoint inhibitor (ICI) therapy has shown a significant benefit in the treatment of a variety of cancer entities. However, immune-related adverse events (irAEs) occur frequently and can lead to ICI treatment termination. MicroRNA-146a (miR-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bddb817444cfc4cfd247a46fdf52174d
https://archive-ouverte.unige.ch/unige:156449

Zobrazit plný text záznamu

Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review

Autor: Marija Gamulin, Eric Nham, Deni Rkman, Zrna Antunac, null Golubić, Robert Likić

Publikováno v: Croatian Medical Journal
Volume 61
Issue 4

Aim To assess diseases outcomes and tolerability of real-life second-line nivolumab in a series of metastatic renal cell carcinoma (mRCC) patients. ----- Methods This retrospective chart review involved prospectively monitored patients (named patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d807a701ee3b39fe7fd1be726737505
https://www.bib.irb.hr/1263395

Zobrazit plný text záznamu

Bullous lichen planus and anti-programmed cell death-1 therapy: Case report and literature review

Autor: C. de Lorenzi, Marem Abosaleh, A. Vuilleumier, Guerkan Kaya, Raphaël André

Publikováno v: Annales de dermatologie et de vénéréologie, Vol. 147, No 3 (2020) pp. 221-227

Summary Background Cutaneous adverse effects of immunotherapies are being seen with increasing frequency in general practice. While anti-PD1 lichenoid reactions are well known, only a few cases of bullous lichen planus have so far been reported in th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76966533d071408e7a6b05818262e81f
https://archive-ouverte.unige.ch/unige:147009

Zobrazit plný text záznamu

Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma

Autor: Annabel Meireson, Piet Ost, Teofila Seremet, Jo Van Dorpe, Liesbeth Ferdinande, Nora Sundahl, Bart Neyns, Lieve Brochez, Vibeke Kruse

Purpose Nivolumab improves survival in patients with metastatic melanoma. Unfortunately, most patients do not respond to this treatment. Preclinical data indicate that radiation therapy could work synergistically with nivolumab and improve response r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1f6019cfc276207deb92a753bddb0b2
https://biblio.vub.ac.be/vubir/phase-2-trial-of-nivolumab-combined-with-stereotactic-body-radiation-therapy-in-patients-with-metastatic-or-locally-advanced-inoperable-melanoma(707a28c4-923a-46bd-96f3-69c0fb0f2a41).html

Zobrazit plný text záznamu

Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient

Autor: Vincent Pillonel, Olivier Michielin, Andreas F. Hottinger, Luis Schiappacasse, Veronica Aedo-Lopez, Gregoire Berthod, Vincent Dunet, Solange Peters

Publikováno v: Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol. 7, no. 1, pp. 336
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-6 (2019)

Background Immune checkpoint inhibitors (ICPis) have revolutionised the treatment of melanoma by significantly increasing survival rates and disease control. However, ICPis can have specific immune-related adverse events, including rare but severe ne

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::405a051ce719beb9bfa688acb52fdc90
https://pubmed.ncbi.nlm.nih.gov/31791418

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání